Related coverage linked through entity extraction aliases.
Apr 21, 2026
A securities class action alleges Corcept misled investors about the regulatory prospects for relacorilant. The suit cites an FDA Complete Response Letter, a 50.4% stock drop, and an April 21, 2026 lead plaintiff deadline.
Apr 14, 2026
Corcept Therapeutics executives and directors were sued over alleged misstatements about a drug candidate’s approval prospects. The suit says insider stock sales totaled $97 million while the stock price was artificially inflated.
Sep 11, 2025
The FDA issued a Complete Response Letter for Corcept's relacorilant as a treatment for hypertension secondary to hypercortisolism, requesting additional evidence of effectiveness despite acknowledging positive trial results.
